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INTRODUCTION
In the United States, Clostridium difficile infection (CDI) occurs at a rate of 150 cases per 100 000 population per year creating a significant burden to patients, relatives and healthcare providers [1] . In modern healthcare, sophisticated medical interventions (e.g. organ transplantation, complex surgery and cancer treatments) come at the cost of an increased infection risk. In particular, antibiotic treatment causes dysbiosis of the host gut microflora and an increased risk of CDI. Complex health needs are unlikely to diminish, and so, together with an aging population, antibiotic stewardship programmes aimed at reducing the use of 'high-risk' antibiotic prescribing should reduce, but not eliminate, the risk of CDI. Strategies to reduce healthcare exposure to C. difficile, such as source isolation of CDI cases and enhanced environmental cleaning, have reduced CDI rates in some regions [2] . However, meticulous adherence to these interventions is unlikely to remove the risk of CDI entirely due the widespread presence of C. difficile in healthcare settings, the environment, livestock and (occasionally) food [3] [4] [5] . Therefore, there is an urgent need for effective CDI prevention and treatment strategies.
Currently, three antimicrobial agents provide the mainstay of CDI therapy; vancomycin, metronidazole and fidaxomicin [6, 7] . Several novel antimicrobial agents are in development and, if successful, may increase the range of agents available to clinicians (Table 1 ). In addition, studies demonstrating the efficacy of faecal microbiota transplantation (FMT) for the treatment of recurrent CDI [8, 9] have sparked interest in CDI interventions designed to target gut dysbiosis that typically involves reduced diversity [10] . These therapies may be particularly helpful for recurrent CDI, which occurs in approximately a quarter of patients following primary infection. Host gut antibody-mediated immunity is also known to be important to CDI pathogenicity [11] , and recent interventional trials have targeted this by using either preemptive vaccination strategies or passive antibodies (in addition to standard therapy). This review summarizes emerging preventive and therapeutic approaches for CDI, with a brief description of each strategy and its stage of development.
CURRENT C. DIFFICILE INFECTION ANTIBIOTICS
The usage of metronidazole and vancomycin for the treatment of CDI has been comprehensively described previously [12] . The most significant recent findings are from a pooled analysis of two phase III trials of tolevamer (a toxin binding polymer), which failed to demonstrate equivalence to standard treatment [13] . These data additionally showed that clinical success occurred significantly less often following metronidazole compared with vancomycin therapy (73 and 81%, respectively, P ¼ 0.02) [13] . However, metronidazole continues as first-line CDI therapy in many countries because of low acquisition cost and the perceived risk of vancomycin-resistant enterococci with vancomycin [6, 7] . Oral vancomycin is often recommended for severe or complicated CDI [6, 7] .
Fidaxomicin was added to the CDI treatment repertoire following Food and Drug Administration (FDA) approval in 2011 [14] . Fidaxomicin is an oral macrocyclic agent that inhibits RNA synthesis and demonstrates relatively little perturbation of the host microbiota [15] whilst achieving high faecal concentrations and reduced toxin and spore levels [16, 17] . In two large phase III trials, fidaxomicin demonstrated noninferiority to vancomycin and was associated with reduced CDI recurrence (15.4% after fidaxomicin versus 25.3% after vancomycin, P ¼ 0.005) [18, 19] . Lower cure rates using fidaxomicin (or vancomyicn) were noted in BI/NAP1/ribotype 027 infections. Fidaxomicin is included in European guidelines on CDI treatment [7] , but usage has been limited by high drug acquisition cost. However, some studies suggest that the cost of this agent can be offset by reduced disease recurrence and shorter hospital admissions [20,21 & ]. A recent before and after design study reported reduced mortality in some settings in which fidaxomicin was the preferred CDI treatment agent [21 & ].
NOVEL ANTIMICROBIAL THERAPY FOR C. DIFFICILE INFECTION
The ideal antimicrobial agent for CDI would reduce vegetative C. difficile cells, toxins and spores in the host gut lumen without encouraging host microbial resistance (e.g. vancomycin-resistant enterococci or multiresistant Gram-negative bacilli), perturbation of the host microbiota [11] or systemic adverse effects. It is enormously challenging for a single agent to meet all these criteria, but a number of promising new therapies are being investigated (summarized in Table 1 ). Surotomycin is an oral lipopeptide antibiotic, which was developed semi-synthetically from daptomycin [22] [23] [24] [25] . A randomized multicentre doubleblind noninferiority controlled phase 2 trial compared surotomycin with vancomycin (n ¼ 210). This study demonstrated noninferiority using 125 and 250 mg surotomycin doses when compared with oral vancomycin (92 and 87 versus 89%, respectively) [26] . Recurrence was lower in the surotomycin groups [28% (125 mg group) and 17% (250 mg group)] compared with vancomycin (36%) but the trial was too small to demonstrate significant outcome differences [27] . However, recent data from phase III trials (NCT01598311 and NCT01597505) comparing surotomycin with vancomycin have failed to demonstrate noninferiority of surotomycin compared with vancomycin [28] . As such, it is doubtful that surotomycin will continue to be developed.
KEY POINTS
C. difficile remains a significant cause of morbidity and mortality worldwide. Current approaches to reduce CDI using antimicrobial stewardship and infection prevention programmes have not led to a consistent marked decline in disease rates.
Historically, two antibiotics (metronidazole and vancomycin) and a recent third (fidaxomicin) have been used routinely for CDI treatment; convincing data are now available showing that metronidazole is the least efficacious agent.
Novel antimicrobial agents are being evaluated in phase III trials; it is not yet clear what will be the roles of these agents in future CDI treatment.
Prophylaxis is an optimum approach to reduce the impact of CDI especially in high-risk populations; monoclonal antibodies, antibiotic blocking approaches and multiple vaccines are currently in advanced clinical trials.
The treatment of recurrent CDI is particularly troublesome, and several different live biotherapeutics are being developed, in addition to faecal microbiota transplantation. Cadazolid (Actelion) is a novel hybrid oxazolidinone-fluroquinolone antibiotic that inhibits C. difficile protein synthesis and, to a lesser extent, DNA synthesis, which is very poorly absorbed after oral twice daily administration, achieving high faecal concentrations but with relatively low impact on host microbiota [29] [30] [31] . A phase II doubleblind, double-dummy, randomized study (n ¼ 84) showed that time to CDI symptom resolution was similar for cadazolid and vancomycin [32 & ]. Cadazolid had a greater sustained response rate (primary cure without recurrence) compared with vancomycin (60, 56, and 47% for 250, 500 and 1000 mg cadazolid, respectively, and 33% for vancomycin). However, this study had an unusually low response rate to vancomycin. A phase III double-blind trial (NCT01987895) investigating noninferiority to vancomycin in terms of clinical response and superiority in terms of sustained response is currently recruiting.
Ridinilazole (SMT19969) is a novel nonabsorbable very narrow-spectrum antimicrobial [33] with minimal activity against host gut microbiota but good activity against selected clostridia including C. difficile [34] [35] [36] [37] . Safety and tolerability has been demonstrated in healthy patients and in a recently completed phase II randomized double-blind trial (CoDIFy) [38,39 && ]. CoDIFy was designed as a noninferiority study and compared oral ridinilazole 200 mg bd with oral vancomycin 125 mg qds, both for 10 days; sustained clinical response rates were 67 and 42%, respectively (n ¼ 69 mITT population). Recurrence occurred in 14% of the ridinilazole group compared with 35% of the vancomycin group; this difference meant that ridinilazole achieved a sustained response rate of 66.7 versus 42.4% for vancomycin, which met preset statistical superiority criteria [39 && ].
C. DIFFICILE INFECTION PROPHYLAXIS
Ribaxamase (SYN-004, synthetic biologics) is a recombinant beta-lactamase which has been formulated as an oral accompaniment to beta-lactam antibiotics [40,41 & ]. This agent degrades unmetabolized antibiotic in the host intestine in order to protect the gut microbiota from dysbiosis and is well tolerated [42] . Animal studies have demonstrated safety without interference with the systemic pharmacokinetics of ceftriaxone [41 & ]. A phase II doubleblind placebo-controlled study is ongoing and will examine safety and whether ribaxamase can reduce CDI risk.
Another novel approach to CDI prophylaxis is DAV132 (DaVolterra), which is an activated charcoal based product in an enteric-coated pill [43 & ].
This adsorbent product irreversibly captures antibiotics in the intestine whilst hopefully avoiding interruption of antibiotic absorption. DAV132 has been examined in a proof-of-concept study involving 18 healthy patients. In-vitro human gut model and in-vivo hamster models also have positive findings but clinical efficacy data are awaited [43 & ].
ACTIVE C. DIFFICILE IMMUNIZATION
Vaccination to boost host antibody-mediated immunity is a promising strategy to reduce CDI. A previous model of CDI vaccination demonstrated cost-effectiveness even with wide-ranging risks of CDI and varied vaccine efficacies and costs [44] . A CDI vaccine is therefore an appealing goal, with the potential for substantial clinical impact in healthcare institutions across the world.
Host immunity to C. difficile infection C. difficile virulence is largely governed by two protein exotoxins, toxin A (TcdA) and toxin B (TcdB). The host immune response to these toxins likely influences the likelihood of disease, clinical severity and outcome of CDI [10] . A previous prospective study in 271 patients demonstrated higher serum immunoglobulin G (IgG) levels to C. difficile TcdA in patients with asymptomatic colonization compared with those with CDI [45] . Furthermore, recurrent CDI has been associated with poor IgG and immunoglobulin M responses supporting the hypothesis that reduced immune response leads to poor outcomes [46] . Serum toxin-neutralizing antibody can be measured to assess C. difficile vaccine efficacy. A good antibody response to TcdA seems most important, but recent evidence suggests that an effective vaccine requires neutralization to both TcdA and TcdB [47] . Other antigens may also be important; antibodies to surface proteins are greater in C. difficile colonized versus infected patients [48] . Ideally, C. difficile vaccines could include targets that reduce primary colonization as well as toxin neutralization.
A key issue for trials is which patients will best benefit from vaccination.
Phase II/III C. difficile vaccines
Three vaccines that use C. difficile toxin targets have reached at least phase II trials. The most advanced is a formalin-inactivated toxoid-based vaccine developed by Sanofi Pasteur [49] . Six phase I trials have demonstrated it to be safe and well tolerated. Seroconversion to TcdA was stronger than TcdB (but took up to 70 days) and response was less common in elderly patients (>65 years). Three doses were required to achieve an adequate neutralizing-antibody response [49, 50] . A randomized placebo-controlled two-stage phase II trial compared low-dose versus high-dose vaccine, both with and without an aluminium hydroxide (AlOH) adjuvant (n ¼ 455), and assessed schedules of administration (n ¼ 206). A 100 mg dose (with AlOH) had the best immunogenic profile and was chosen for future trials [51 & ]. A phase III trial to assess the safety and efficacy of this vaccine in preventing primary CDI in at-risk patients aged greater than 50 years is ongoing (predicted completion in 2017; NCT01887912).
Another vaccine, developed by Pfizer, is also formalin-inactivated but has mutations in Tcd A and TcdB to reduce toxigenicity [52] . A phase I placebo-controlled, randomized, observer-blinded study demonstrated efficacy with three parenteral doses [53 & ]. Phase II randomized observer-blinded studies, because of complete shortly, are comparing this vaccine with placebo in 65-85 year olds (NCT02117570 and NCT02561195). The primary outcomes include TcdA and TcdB neutralizing antibody responses and an assessment of vaccine-related adverse effects.
C. difficile toxins are difficult to purify and may degrade over time, making them challenging vaccine candidate antigens. For this reason, a vaccine (VLA84, Valneva) containing recombinant toxin domains is being developed, and has satisfactorily completed an open-label phase I study assessing safety, immunogenicity and dose-response in healthy patients. A press release in 2015 stated that a phase II trial of 500 US/German volunteers demonstrated safety and good immunogenicity, but further data are not yet available [54] . A phase III programme is being planned. Oral vaccination is another possibility, potentially using a vector such as Bacillus subtilis spores; CDVAX uses this method but is only at an early stage of development [55] .
PASSIVE C. DIFFICILE PROTECTION: MONOCLONAL ANTIBODIES
Serum antitoxin antibodies afford natural protection against recurrent CDI, but we do not understand what controls the production of these by some but not all individuals. There are no routinely available tests to measure antitoxin antibodies (in either serum or faeces). Bezlotoxumab has been developed as a human monoclonal antibody that binds to and neutralizes C. difficile toxin B. It is given as a single infusion during standard of care CDI antibiotic therapy. In phase III clinical trials, bezlotoxumab was compared with actoxumab (a monoclonal antibody to toxin A), a combination of actoxumab and bezlotoxumab [56 && ]. The primary endpoint was recurrent CDI, after initial clinical cure, within 12 weeks. Actoxumab was found to be ineffective at a planned interim analysis, and so was ceased. Bezlotoxumab had no effect on the initial clinical cure of CDI, but significantly reduced recurrence rates compared with placebo [17 versus 27%, À10.0 95% confidence interval (CI) À14.0 to À6.0; P 0.0003]; actoxumab and bezlotoxumab did not confer additional protection against recurrence. The 40% relative reduction in CDI recurrence achieved by bezlotoxumab was maintained across 4 versus 8 versus 12 weeks of follow up. Also, recurrence rate were lower in predefined subgroups with high risk of recurrent CDI and/or adverse outcome, including patients aged at least 65 years, those with CDI in the past 6 months, severe CDI, and the immunocompromized. The safety profile of bezlotoxumab was similar to that of placebo. In-patients treated with bezlotoxumab compared with placebo had fewer CDI-associated hospital readmissions (4.0 versus 9.6%, difference À5.7%; 95% CI, À8.8 to À2.7) and all-cause readmissions (23.2 versus 26.9%, difference À3.7%; 95% CI, À9.0 to 1.5) in the 30 days after discharge, in a post-hoc analysis [57 & ]. Notably, bezlotoxumab was also associated with significant reductions in CDI-associated hospital readmissions in inpatients aged at least 65 years, with a history of at least one CDI episode in the past 6 months, and cases with clinically severe CDI.
A FDA Antimicrobial Drugs Advisory Committee voted 10 to 5 (1 abstention) in June 2016 to recommend bezlotoxumab injection for the prevention of CDI recurrence (http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMee tingMaterials/Drugs/Anti-InfectiveDrugsAdvisory-Committee/UCM505290.pdf). If approved for the prevention of recurrent CDI (decision expected in late 2016), bezlotoxumab would be the first therapeutic to attain this indication.
MICROBIOME-BASED THERAPEUTICS
Live biotherapeutics drugs (as opposed to foodstuffs) are regulated by the FDA in a similar manner to drugs. An investigational new drug application is required, and the drug must be safe, pure, potent and consistently produced according to good manufacturing practices.
Faecal microbiota transplantation
The evidence base concerning the effectiveness of FMT continues to grow, notably following the publication of the first randomized controlled trial in 2013 [58] . FMT is still essentially an experimental, nonstandardized procedure, but attracts considerable interest and support, not least because of unmet patient needs for effective therapies for multiple recurrences of CDI. The potential benefits and risks of FMT are summarized in Table 2 . Organizations such as Openbiome aim to overcome some of the practical barriers to FMT, by facilitating access to screened faecal transplant material (http://www. openbiome.org/impact/). Potential safety issues surrounding the administration of live faeces-derived mixtures of microorganisms, are a concern; such biotherapeutics may include species of unknown significance, which could be beneficial or harmful, including noncultivable/unknown microbes. The longer-term consequences of manipulation of the gut microbiota are unknown. Such issues underlie the restrictions that different regulatory authorities have imposed on the use of FMT, primarily to safeguard patient interests. These include in some settings the need for an investigational new drug, and requirements for consenting patients, screening of donors and recipients. Furthermore, the need for faecal material preparation and delivery via either rectal or nasogastro/duodenal routes mean that there are intensive endeavours to develop alternatives to FMT, which can reduce risk and/or simplify delivery, and yet still harness the beneficial properties of the gut microbiota.
Recent studies have examined the use of freeze-thawed and encapsulated material for FMT [59 && ,60] . Freeze-thawed versus fresh faeces delivered via an enema achieved rates of clinical resolution without recurrence up to 13 weeks compared with that were not significantly different in per-protocol (83.5 versus 85.1%) and mITT (75.0 versus 70.3%) populations [59 && ]. However, about one third of the patients in each treatment group, who were ultimately classified as resolved according to the study protocol, required two FMTs. It is a relatively common finding that repeat FMT administration is required to prevent recurrences.
A small nonblinded, nonrandomized study of encapsulated (and freeze-thawed) faeces was carried out in 20 patients with at least three episodes of mild-to-moderate CDI and failure of a 6-8 weeks of vancomycin therapy or at least two episodes of severe CDI requiring hospitalization [32 & ]. Resolution of diarrhoea was achieved in 14 patients (70%; 95% CI, 47-85%) after a single capsule-based FMT; four out of six retreated nonresponders had resolution of diarrhoea, resulting in an overall 90% (95% CI, 68-98%) response rate. No serious adverse events were attributed to FMT. 
Live biotherapeutic microbiota preparations
RBX2660 is a live biotherapeutic microbiota suspension that aims to harness the effectiveness of FMT, but within a standardized, regulated product, for the treatment of recurrent CDI. In the first of two phase II studies, 34 patients (with !2 recurrent CDI episodes or !2 severe episodes resulting in hospitalization) received at least one dose of RBX2660 and 31 completed 6 months follow up [61 && ]. Following a 10-14 day course of CDI antibiotics and a 24-48 h washout period, RBX2660 was administered as a single dose via enema. Further recurrent CDI occurred in 48% of patients after one dose of RBX2660, with 15 out of 31 patients receiving a second enema; of these, 78.6% were considered to be treatment successes, contributing to an overall success rate of 27 out of 31 (87.1%). A second phase II study has recently been completed, but results are not yet available.
SER-109 (Seres) is also a live biotheraputic that comprises an encapsulated mixture of purified Firmicutes spores, derived from human faeces. As the spores are resilient to manipulation, ethanol treatment has been used to theoretically reduce the risk of transmissible, harmful infectious agents contaminating the therapeutic product. Seres has completed two phase II studies of SER-109. The first of these was a noncomparative study in patients with at least three CDI episodes in the previous 12 months [62 && ]; 26 out of 30 patients (86.7%) across two dosing groups met the primary efficacy end point (absence of C. difficile-positive diarrhoea during 8 weeks of follow-up); 96.7% of patients were considered to have achieved clinical resolution, as three patients with early, self-limiting C. difficile-positive diarrhoea did not require antibiotic treatment. Notably, the loss of diversity of gut microbiota that is typical in patients with CDI rapidly reversed after receipt of SER-109. The interim results of the second, recently completed, phase II (ECOSPORE) study of SER-109 have just been released (http://ir.serestherapeutics. com/phoenix.zhtml?c=254006&p=irol-newsArticle &ID=2190006). SER-109 was not effective overall at reducing CDI recurrence, but was efficacious in patients aged at least 65 years old, in whom CDI recurrence occurred in 14 out of 31 (45%) of patients who received SER-109 versus 12 out of 15 (80%) of those who received placebo. Further analyses will be important to understand these results.
Nontoxigenic C. difficile
A randomized, double-blind, placebo-controlled, dose-ranging study examined the efficacy of a nontoxigenic C difficile (NTCD) strain to prevent recurrent CDI, presumably by displacing (blocking) toxigenic bacteria remaining after CDI antibiotic treatment [63 && ]. About two thirds (69%) of NTCD recipients were colonized, with only a 2% CDI recurrence rate in these patients. However, of those not colonized by NTCD, recurrence occurred in 31% (similar to placebo). Of note, none of the patients who were colonized at week 6 remained colonized by week 26.
CONCLUSION
There are a number of promising approaches aimed at tackling the global challenge of CDI. However, further trials are required to determine which, if any, can take a role in the routine primary prevention, treatment and/or secondary prevention of CDI.
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